Dr. Spigel Discusses the Development of Onartuzumab for the Treatment of Lung Cancer

Video

In Partnership With:

David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, discusses the development of onartuzumab for the treatment of patients with lung cancer.

David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, discusses the development of onartuzumab for the treatment of patients with lung cancer.

Onartuzumab showed benefit initially in a phase II trial with regard to progression-free survival (PFS) and overall survival (OS) in combination with erlotinib for patients with refractory MET-positive lung cancer. Onartuzumab also showed activity in other settings in combination with other drugs. A phase III study of about 500 patients, however, showed no advantage to PFS, OS, or response rate.

Another MET inhibitor, tivantinib, also showed no benefit in patients with refractory non-small cell lung cancer.

Several questions remain regarding MET inhibitors, Spigel says, but it is known that the MET signaling pathway is important in oncogenesis.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD